2Q Financial Markets Preview: Three legs to stand on

Following the across-the-board equity market sell-off in late February, there are as many opinions about where the markets are heading as there are Street watchers, making the question hardly worth pursuing.

There's little question that overall market conditions, combined with persistent concern that Amgen Inc.'s erythropoietin franchise could be eroding, have set a tone of uncertainty in the biotech space. But despite the uncertainty of the markets, there is consensus that fundraising, partnering and M&A will continue to be robust. ...